Active Ingredient History
Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract and one of the 32 species that belong to the genus Bifidobacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants. When grown on general anaerobic medium, B. longum forms white, glossy colonies with a convex shape. B. longum is one of the most common bifidobacteria present in the gastrointestinal tracts of both children and adults. B. longum is non-pathogenic, is often added to food products, and its production of lactic acid is believed to prevent growth of pathogenic organisms. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Pain (Phase 2/Phase 3)
Acute-On-Chronic Liver Failure (Phase 2/Phase 3)
Adenomatous Polyposis Coli (Phase 2)
Aged (Early Phase 1)
Ascites (Phase 2)
Asthma (Phase 1/Phase 2)
Bipolar Disorder (Phase 2)
Celiac Disease (Phase 4)
Cognitive Dysfunction (Phase 4)
Colic (Phase 4)
Colitis, Ulcerative (Phase 2/Phase 3)
Crohn Disease (Phase 4)
Deglutition Disorders (Early Phase 1)
Dermatitis, Atopic (Phase 1)
Diabetes Mellitus (Phase 2)
Diarrhea (Phase 2/Phase 3)
Drug Resistance, Bacterial (Phase 2)
Esophageal and Gastric Varices (Phase 3)
Fatty Liver (Phase 1/Phase 2)
Fibrosis (Phase 4)
Food Hypersensitivity (Phase 1)
Gastroenteritis (Phase 3)
Gastrointestinal Microbiome (Phase 3)
General Surgery (Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 2)
Hepatic Encephalopathy (Phase 4)
Hirschsprung Disease (Phase 2)
Hyperoxaluria (Phase 1/Phase 2)
Hypersensitivity (Phase 4)
Infant, Low Birth Weight (Phase 2/Phase 3)
Inflammation (Phase 2)
Inflammatory Bowel Diseases (Phase 3)
Intestinal Neoplasms (Phase 2/Phase 3)
Irritable Bowel Syndrome (Phase 4)
Kidney Failure, Chronic (Phase 2)
Klebsiella pneumoniae (Phase 1/Phase 2)
Liver Cirrhosis (Phase 2/Phase 3)
Neonatal Sepsis (Phase 3)
Nephrolithiasis (Phase 1/Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 1/Phase 2)
Osteoporosis (Phase 2)
Pediatrics (Phase 3)
Peritonitis (Phase 2/Phase 3)
Probiotics (Phase 4)
Psoriasis (Phase 1/Phase 2)
Scleroderma, Systemic (Phase 2)
Severe Acute Malnutrition (Phase 2)
Thinness (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
